BriaCell Therapeutics Corp. (NASDAQ:BCTX) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on February 12, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
BriaCell Therapeutics Corp.'s stock currently trades at $4.09 with a market capitalization of $19.5M.
